Skip to main content
DaehanPharmaceutical logo

DaehanPharmaceutical — Investor Relations & Filings

Ticker · 023910 ISIN · KR7023910003 KO Manufacturing
Open in API
Filings indexed 297 across all filing types
Latest filing 2024-12-16 Notice of Dividend Amou…
Country KR South Korea
Listing KO 023910

About DaehanPharmaceutical

https://www.dhnp.co.kr/

Daehan Nupharm is a pharmaceutical company engaged in the research, development, and manufacturing of a diverse portfolio of healthcare products. The company's business is structured around four core areas: human pharmaceuticals, offering a range of therapeutic treatments; animal health products for both companion and livestock animals; advanced bio-pharmaceuticals, with a focus on next-generation technologies like cell therapy; and health functional foods. Established initially in the animal health sector, the company leverages its dedicated Central and Bio Research Institutes to drive innovation and develop solutions for global markets. The R&D efforts concentrate on strengthening technological capabilities and advancing new treatment modalities.

Recent filings

Filing Released Lang Actions
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 1% confidence The document is a short regulatory announcement from a Korean company (Daehan Pharmaceutical) regarding the setting of a record date and shareholder register closure period for the purpose of holding an upcoming Annual General Meeting. It does not contain the full meeting materials or proxy statements, but rather serves as a formal notice of the record date. Given its nature as a regulatory notification regarding corporate governance procedures, it fits best under the RNS category.
2024-12-16 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share transactions (purchases) made by an executive (Lee Yoon-woo) of Daehan Pharmaceutical Co., Ltd. This type of filing is a standard regulatory requirement for insider trading/shareholding disclosures, which corresponds to the 'Director's Dealing' category.
2024-12-10 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS) and Korea Exchange. It details specific share transactions (장내매수 - open market purchases) by an executive (Lee Yoon-woo) of Daehan Pharmaceutical Co., Ltd. This type of filing is a standard regulatory disclosure for insider trading/shareholding changes by directors and major shareholders, which corresponds to the 'Director's Dealing' category.
2024-11-21 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details a transaction (장내매수 - open market purchase) by an executive (Lee Seung-young) of Daehan Pharmaceutical Co., Ltd. This is a standard regulatory filing for insider trading/director's dealing, which corresponds to the 'Director's Dealing' category.
2024-11-21 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for '대한약품공업주식회사' (Daihan Pharm Co., Ltd.) covering the period from January 1, 2024, to September 30, 2024. It contains detailed financial information, business operations, and management analysis, which fits the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service and Korea Exchange. It details specific share transactions (장내매수 - open market purchases) by an executive (Lee Yoon-woo) of Daehan Pharmaceutical Co., Ltd. This type of filing is a standard regulatory disclosure for insider trading/director dealings.
2024-11-13 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.